{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:02:02Z","timestamp":1775790122748,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clml.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T13:35:11Z","timestamp":1655040911000},"page":"e915-e921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5258-2140","authenticated-orcid":false,"given":"Chantiya","family":"Chanswangphuwana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-4449","authenticated-orcid":false,"given":"Chantana","family":"Polprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smith","family":"Kungwankiattichai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekarat","family":"Rattarittamrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-4889","authenticated-orcid":false,"given":"Thanawat","family":"Rattanathammethee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-7636","authenticated-orcid":false,"given":"Wasithep","family":"Limvorapitak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supawee","family":"Saengboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pimjai","family":"Niparuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teeraya","family":"Puavilai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakrawadee","family":"Julamanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirun","family":"Saelue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinadol","family":"Wanitpongpun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chajchawan","family":"Nakhakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kannadit","family":"Prayongratana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantrapa","family":"Sriswasdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.06.005_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.06.005_bib0002","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Update to","first-page":"129","article-title":"Acute myeloid leukaemia and related precursor neoplasm","author":"Arber","year":"2017"},{"key":"10.1016\/j.clml.2022.06.005_bib0003","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.06.005_bib0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","article-title":"Sense and nonsense of high-dose cytarabine for acute myeloid leukemia","volume":"121","author":"L\u00f6wenberg","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.005_bib0005","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","article-title":"High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial","volume":"31","author":"Schaich","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.005_bib0006","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","article-title":"A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study","volume":"117","author":"Miyawaki","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.005_bib0007","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1158\/1078-0432.CCR-19-3433","article-title":"Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia","volume":"26","author":"Wei","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.06.005_bib0008","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","article-title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222","volume":"105","author":"Moore","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.005_bib0009","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1182\/blood-2011-04-349258","article-title":"Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study","volume":"118","author":"Thomas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.005_bib0010","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-015-2389-9","article-title":"Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.06.005_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11596-018-1845-x","article-title":"Comparison of mitoxantrone in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for young non-APL acute myeloid leukemia patients with favorable and intermediate cytogenetics","volume":"38","author":"Zhou","year":"2018","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.clml.2022.06.005_bib0012","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.005_bib0013","doi-asserted-by":"crossref","first-page":"9509","DOI":"10.1038\/s41598-017-10368-0","article-title":"Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2022.06.005_bib0014","first-page":"643","article-title":"A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia","volume":"32","author":"Fukushima","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2022.06.005_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/16078454.2021.1912949","article-title":"Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients","volume":"26","author":"Tangchitpianvit","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2022.06.005_bib0016","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","article-title":"Cytarabine dose of 36 g\/m\u00b2 compared with 12 g\/m\u00b2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study","volume":"29","author":"Schaich","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.005_bib0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.005_bib0018","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.17462","article-title":"High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature","volume":"194","author":"Kolla","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.06.005_bib0019","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.06.005_bib0020","article-title":"High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.06.005_bib0021","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","article-title":"Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis","volume":"130","author":"Magina","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.005_bib0022","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2022.06.005_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CIA.S343598","article-title":"Standard-intensity induction and intermediate\/high-dose cytarabine consolidation can improve survival for elderly patients with newly diagnosed acute myeloid leukemia: a retrospective cohort study","volume":"17","author":"Wang","year":"2022","journal-title":"Clin Interv Aging"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:46:59Z","timestamp":1729856819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2152265022001896"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.06.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}